Background: Recombinant human endostatin (rh-endostatin) plus standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients has shown improved efficacy however, it is unclear whether it is effective and safe when added to pemetrexed/cisplatin and used as.
Rh-endostatin normalizes the architecture of the tumor vasculature. We examined the effect of rh-endostatin on the morphology of blood vessels in the Lewis lung cancer tumors by confocal microscopy. Normal skeletal muscle has an organized vasculature with a.
Background: Recombinant human endostatin (rh-endostatin) is an inhibitor of tumor angiogenesis that acts on neovascular endothelial cells. Previous studies showed improved clinical outcome for rh-endostatin plus standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
Previous study has proven that rh-endostatin, which has synergistic effect when combined with chemotherapeutics, can improve the efficacy of chemotherapy for non-small cell lung cancer and has a …
10/1/2011 · Adding rh-endostatin to standard platinum-based chemotherapy may significantly improve progression-free and overall survival in patients with advanced non–small cell lung cancer (NSCLC), but the cost-effectiveness of this practice is unclear.
Objective: To evaluate the treatment efficacy and safety with the combination of rh-endostatin (YH-16) and chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: 34 patients with advanced non-small cell lung cancer confirmed by histopathology or cytopathology were administrated with YH-16 7.5 mg/m2 (day 1-14) and routine chemotherapy every 3 weeks.
1/2/2018 · A number of clinical studies have demonstrated the significant survival benefit of rh-endostatin in treating late stage non-small-cell lung carcinoma ( NSCLC). As a result, rh-endostatin (commercial name of Endostar) was approved by the State Food and Drug Administration of China (CFDA) in September of 2005 as a treatment option for NSCLC.
2/26/2021 · Yang L, Wang JW, Cui CX, et al. Rh-endostatin (YH-16) in combination with vinorelbine and cisplatin for advanced non-small cell lung cancer : a multicenter phase II trial. Zhongguo Fei Ai Za Zhi. 200514:204–7. Google Scholar 23.
6/1/2005 · Background: Endostar (rh-endostatin, YH-16) is a new recombinant human endostatin developed by Medgenn Co. Ltd. Pre-clinical study indicates that it can inhibit tumor endothelial cell proliferation, angiogenesis, and tumor growth. Phase I and Phase II studies revealed that Endostar was effective as single agent with good tolerance in clinical use.
1/10/2012 · Wang JW, Sun Y, Liu YY, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Chinese), 2005, 8: 283–290. Google Scholar
